Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jul 6;5(7):1188–1203. doi: 10.1038/s42255-023-00834-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 5 — a, Experimental outline: human liver spheroids of hepatocytes and NPCs or with hepatocytes and NPCs where LM2 have been depleted (NPCs − LM2) using FACS were treated with high levels of FFAs, glucose and insulin (steatogenic media, SM) for 1 week. b, Protein quantification of PRDX2 levels in the media of liver spheroids after 7 days of treatment with SM (SM all NPCs versus NPCs − LM2, P = 0.0008; all NPCs SM versus control, P = 0.0040). c, Quantification of intracellular lipids in liver spheroids upon treatment with SM for 7 days (all NPCs SM versus control, P = 0.0339). FC, fold change. d, ROS (H₂O₂) content in media after 48 h and 7 days of treatment with SM (all NPCs SM versus control, P = 0.0002 (48 h) and P = 0.0263 (7 days); NPCs − LM2 SM versus control, P < 0.0001 (48 h) and P < 0.0001 (7 days); SM all NPC versus NPCs − LM2, P = 0.0050 (48 h) and P = 0.0016 (7 days)). e, Intracellular ROS and RNS in liver spheroids after 7 days of treatment with SM (all NPCs SM versus control, P < 0.0001; NPCs − LM2 SM versus control, P < 0.0001; SM all NPC versus NPCs − LM2, P = 0.0415). f, Lipid peroxidation by-product (MDA) content in liver spheroids after 7 days of treatment with SM (all NPCs SM versus control, P = 0.0002; NPCs − LM2 SM versus control, P < 0.0001; SM all NPC versus NPCs − LM2, P = 0.0213). g, Experimental outline: human primary hepatocytes were co-cultured with LM2 cells at a 1:2 or 1:4 ratio (LM2:Hep) and treated with SM for 48 h. h, ROS (H₂O₂) content in media after treatment with SM (Hep alone SM versus control, P < 0.0001; SM Hep alone versus LM2:Hep (1:4), P = 0.0346; SM Hep alone versus LM2:Hep (1:2), P = 0.0243). n = pooled liver spheroids from 1 hepatocyte donor and 3 NPC donors (a–f) or from 3 hepatocyte donors and 1 NPC donor (g, h). Data are presented as mean ± s.e.m. P values were calculated by one-way (b–f) or two-way (h) ANOVA with adjustment for multiple comparisons. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Illustrations in g were partly created using components adapted from Servier Medical Art, provided by Servier, licensed under a Creative Commons Attribution 3.0 unported license.

Source data